

## Senate Public Health And Welfare Committee Testimony of Kansas Independent Pharmacy Service Corporation (KPSC) Opposition to HB 2107 March 16, 2017

Chairwoman Schmidt and Members of the Committee,

This testimony is submitted by Kansas Independent Pharmacy Service Corporation (KPSC), which has served independent pharmacies in Kansas for 32 years with a very competitive national retail buying program and with many advocacy services that point to the key role which community independent pharmacies play in the health and well-being of Kansas citizens.

KPSC is in opposition to HB 2107 as it would require pharmacies dispensing the biological products in question to communicate/report the dispensing of such products in a manner that is accessible to prescribers, in addition to their usual claim adjudication to a pharmacy benefits management company (PBM). The extra work needed to complete this communication does not appear to involve additional compensation to a pharmacy. We suggest a modest flat fee for completion of this extra activity. As an alternative, PBMs collect data on all prescriptions dispensed and may more appropriately be able to send a communication to prescribers.

Also, it appears that there are very few of the biological products for which this bill is addressed, making it difficult to currently assess whether the federal Food and Drug Administration (FDA) may deem any as interchangeable or whether any to be dispensed may benefit from the inclusion of some type of utilization management tools. It would be better to allow such biological products, their planned introduction/growth, the possible need for added communications, allowance for interchangeability and other related matters to be the subject of interim study. This would allow more discussion and debate for all impacted parties before contemplating possible legislation to shape utilization of such drugs.

Thank you for the opportunity to present this testimony to the Committee. If you have any questions on our testimony, please contact KPSC CEO Peter Stern by e-mail at <a href="mailto:pstern@kspharmserv.com">pstern@kspharmserv.com</a> or by phone at 785-228-1695.